When stratified by the tumor type, the ORRs in HER2 mutation and wild-type subgroups were respectively 100% (1/1) and not available for anal cancer, 50% (1/2) and 48% (12/25) for bladder cancer (BLCA), 0 (0/1) and 18.2% (2/11) for HNSC, 100% (2/2) and 27.3% (15/55) for lung cancer (p=0.027), and 33.3% (4/12) and 22.9% (47/205) for melanoma (Table S4). Here, ERBB2 is linked to anal carcinoma.